» Articles » PMID: 23295931

Activities of Drug Combinations Against Mycobacterium Tuberculosis Grown in Aerobic and Hypoxic Acidic Conditions

Overview
Specialty Pharmacology
Date 2013 Jan 9
PMID 23295931
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Mycobacterium tuberculosis is exposed to hypoxia and acidity within granulomatous lesions. In this study, an acidic culture model of M. tuberculosis was used to test drug activity against aerobic 5-day-old (A5) and hypoxic 5-, 12-, and 19-day-old (H5, H12, and H19, respectively) bacilli after 7, 14, and 21 days of exposure. In A cultures, CFU and pH rapidly increased, while in H cultures growth stopped and pH increased slightly. Ten drugs were tested: rifampin (R), isoniazid (I), pyrazinamide (Z), ethambutol (E), moxifloxacin (MX), amikacin (AK), metronidazole (MZ), nitazoxanide (NZ), niclosamide (NC), and PA-824 (PA). Rifampin was the most active against A5, H5, H12, and H19 bacilli. Moxifloxacin and AK efficiently killed A5 and H5 cells, I was active mostly against A5 cells, Z was most active against H12 and H19 cells, and E showed low activity. Among nitrocompounds, NZ, NC, and PA were effective against A5, H5, H12, and H19 cells, while MZ was active against H12 and H19 cells. To kill all A and H cells, A5- and H5-active agents R, MX, and AK were used in combination with MZ, NZ, NC, or PA, in comparison with R-I-Z-E, currently used for human therapy. Mycobacterial viability was determined by CFU and a sensitive test in broth (day to positivity, MGIT 960 system). As shown by lack of regrowth in MGIT, the most potent combination was R-MX-AK-PA, which killed all A5, H5, H12, and H19 cells in 14 days. These observations demonstrate the sterilizing effect of drug combinations against cells of different M. tuberculosis stages grown in aerobic and hypoxic acidic conditions.

Citing Articles

Microwave-assisted chemoselective synthesis and photophysical properties of 2-arylazo-biphenyl-4-carboxamides from hydrazonals.

Alazemi A, Dawood K, Al-Matar H, Tohamy W RSC Adv. 2023; 13(36):25054-25068.

PMID: 37614785 PMC: 10442861. DOI: 10.1039/d3ra04558g.


Eradication of Drug-Tolerant 2022: Where We Stand.

Lanni A, Iacobino A, Fattorini L, Giannoni F Microorganisms. 2023; 11(6).

PMID: 37375013 PMC: 10301435. DOI: 10.3390/microorganisms11061511.


Investigation of Multi-Subunit DNA-Directed RNA Polymerase and Its Rifampicin Resistant Mutants.

Monama M, Olotu F, Tastan Bishop O Int J Mol Sci. 2023; 24(4).

PMID: 36834726 PMC: 9965755. DOI: 10.3390/ijms24043313.


Dormancy: How to Fight a Hidden Danger.

Salina E, Makarov V Microorganisms. 2022; 10(12).

PMID: 36557586 PMC: 9784227. DOI: 10.3390/microorganisms10122334.


Activation of the SigE-SigB signaling pathway by inhibition of the respiratory electron transport chain and its effect on rifampicin resistance in Mycobacterium smegmatis.

Oh Y, Lee H, Jeong J, Kim S, Oh J J Microbiol. 2022; 60(9):935-947.

PMID: 35913593 DOI: 10.1007/s12275-022-2202-0.


References
1.
Dhillon J, Lowrie D, Mitchison D . Mycobacterium tuberculosis from chronic murine infections that grows in liquid but not on solid medium. BMC Infect Dis. 2004; 4:51. PMC: 534102. DOI: 10.1186/1471-2334-4-51. View

2.
Kohanski M, Dwyer D, Hayete B, Lawrence C, Collins J . A common mechanism of cellular death induced by bactericidal antibiotics. Cell. 2007; 130(5):797-810. DOI: 10.1016/j.cell.2007.06.049. View

3.
Diacon A, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald P . 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet. 2012; 380(9846):986-93. DOI: 10.1016/S0140-6736(12)61080-0. View

4.
Fattorini L, Iona E, Ricci M, Thoresen O, Orru G, Oggioni M . Activity of 16 antimicrobial agents against drug-resistant strains of Mycobacterium tuberculosis. Microb Drug Resist. 2000; 5(4):265-70. DOI: 10.1089/mdr.1999.5.265. View

5.
Tasneen R, Li S, Peloquin C, Taylor D, Williams K, Andries K . Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother. 2011; 55(12):5485-92. PMC: 3232786. DOI: 10.1128/AAC.05293-11. View